Nicole Chase, MD
Allergy & Immunology · Saint Paul, MNNPI 1568646057
Payments from drug & device makers
Across 1,844 payments — averaging $978.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$551K
- AstraZeneca$498K
- Regeneron Healthcare Solutions, Inc.$496K
- Incyte Corporation$71K
- Genentech USA, Inc.$45K
- Novartis$28K
- plus $114K from 40 others
Across 3 payments — averaging $2276.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$238,35613%
- Speaking & faculty fees$1,271,32671%
- Grants$4950%
- Travel & lodging$260,67914%
- Food & beverage$29,6672%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,803,467 in reported general payments places this provider in the 95th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 79 | $251,414 |
| Dupixent SyringeDupilumab | 17 | $95,341 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $67,968 |
| Dupixent PenDupilumab | 13 | $48,131 |
| XhanceFluticasone Propionate | 24 | $24,997 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $16,229 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $14,510 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,804 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $10,551 |
| Fluticasone Propionate HfaFluticasone Propionate | 15 | $10,139 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $8,377 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,898 |
| ZetonnaCiclesonide | 12 | $3,059 |
| Azelastine Hcl | 88 | $2,912 |
| Ipratropium Bromide | 44 | $2,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $7,984 | $251,41479 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $24,371 | $84,19786 claims |
| Optinose US, Inc.Xhance | $37 | $24,99724 claims |
| Boehringer IngelheimSpiriva Respimat | $47 | $13,80418 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $497,748 | $13,10349 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $92 | $3,89813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 allergy & immunology providers in Minnesota.
Other allergy & immunology in Saint Paul
- Niladri AichbhaumikSaint Paul$68K
- Roula AltishehSaint Paul$468
- Timothy LindSaint Paul$375
- Micah KarasovSaint Paul$145
- John WahlstromSaint Paul$79
- Jason RaaschPlymouth$2.2M
- Elina JerschowRochester$1.4M
- Thanai PongdeeRochester$1.3M
- Srinivasan RamanujaMankato$352K
- Gerald VolcheckRochester$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.